Clinical Trial

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Study acronym: LUTACT
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-28; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-11-26
Trial Details
NCT Number NCT07054346
Lead Sponsor Thomas Hope
Collaborators: Novartis
Conditions Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
Enrollment 45 participants
Start Date 2025-07-08
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-01